Negative Arcoxia Review May Reflect Increasingly High Hurdle For Me-Toos
Executive Summary
The Arthritis Drugs Advisory Committee's negative review of Merck's Arcoxia could be more indicative of the increasingly challenging regulatory environment for "me too" products than concerns over the Vioxx follow-on's safety profile
You may also be interested in...
Restricted Distribution Should Be Limited To Drugs With Unique Benefit – FDA
Risk management plans that include restricted distribution components should be limited to products that offer a unique benefit in a specific group of patients, according to FDA
Restricted Distribution Should Be Limited To Drugs With Unique Benefit – FDA
Risk management plans that include restricted distribution components should be limited to products that offer a unique benefit in a specific group of patients, according to FDA
Arcoxia Needs Further Study In 1,000s Of Patients, Or Discontinuation – Cmte
Merck's COX-2 inhibitor Arcoxia requires significant additional clinical safety and efficacy evaluation prior to approval, members of FDA's Arthritis Drugs Advisory Committee said in recommending against approval of the Vioxx follow-on for treatment of osteoarthritis